Tonix Pharmaceuticals shares are trading lower. The company announced the first patient has been dosed in the Phase 2, single-blind, placebo-controlled, proof of concept trial of TNX-1300 for the treatment of acute cocaine intoxication in the emergency department.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals shares are trading lower following the announcement of the first patient being dosed in a Phase 2 trial for TNX-1300, aimed at treating acute cocaine intoxication.
August 20, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tonix Pharmaceuticals shares are experiencing a decline after the company announced the dosing of the first patient in a Phase 2 trial for TNX-1300, a treatment for acute cocaine intoxication.
The announcement of a new trial phase can lead to uncertainty among investors, especially if the market perceives potential risks or costs associated with the trial. The decline in share price suggests a negative short-term reaction.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100